The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.
 
Kazufumi Kobayashi
No Relationships to Disclose
 
Sadahisa Ogasawara
Honoraria - AstraZeneca/Daiichi Sankyo; Bayer; Chugai Pharma; Eisai; Lilly; Merck
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Lilly; Merck
Research Funding - AstraZeneca; Bayer; Chugai Pharma; Eisai; Lilly
 
Susumu Maruta
No Relationships to Disclose
 
Tomomi Okubo
No Relationships to Disclose
 
Michihisa Moriguchi
Consulting or Advisory Role - Bayer Yakuhin; Chugai Pharma; Eisai; Lilly Japan
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Eisai; Lilly Japan; Takeda
Research Funding - Bayer Yakuhin; Bristol-Myers Squibb; Eisai; MSD K.K
 
Hiroaki Kanzaki
No Relationships to Disclose
 
Keisuke Koroki
No Relationships to Disclose
 
Naoya Kanogawa
No Relationships to Disclose
 
Yuki Shiko
No Relationships to Disclose
 
Yosuke Inaba
No Relationships to Disclose
 
Kazuyoshi Nakamura
Stock and Other Ownership Interests - Chugai Pharma; Daiichi Sankyo
 
Ryosaku Azemoto
No Relationships to Disclose
 
Kenji Ito
No Relationships to Disclose
 
Shinichiro Okabe
No Relationships to Disclose
 
Masanori Atsukawa
Honoraria - Eisai
Research Funding - Eisai
 
Ei Itobayashi
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Incyte; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Naoki Morimoto
Honoraria - Abbvie; Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Gilead Sciences; Janssen; Kowa; Lilly; Sumitomo Dainippon Pharma; Takeda
Research Funding - Abbvie; EA Pharma; Eisai; Kowa
 
Yoshito Itoh
Speakers' Bureau - Chugai Pharma; Lilly Japan; Merck Sharp & Dohme; Takeda
Research Funding - Baber AG; Chugai Pharma; Eisai; Lilly Japan; Merck Sharp & Dohme; Takeda
 
Naoya Kato
Speakers' Bureau - Abbott; Abbvie; Aska Pharmaceutical Co., Ltd.; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb Company; Chugai Pharma; Covidien; Daiichi Sankyo Co.,Ltd.; EA Pharma; Eisai; Fujifilm; Gilead Sciences; Kowa; Lilly Japan; Mitsubishi Tanabe Pharma; Miyarisan pharmaceutical; Mochida Pharmaceutical Co. Ltd.; MSD K.K; Mylan; Nichi-iko; Nippon Kayaku; Nobelpharma; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Takeda; Tsumura & Co.; Zeria Pharmaceutical
Research Funding - Abbvie (Inst); Asahi Kasei (Inst); Asahi Kasei (Inst); Aska Pharmaceutical Co.,Ltd. (Inst); Astellas Pharma (Inst); Boston Scientific (Inst); Chugai Pharma (Inst); Covidien (Inst); CYTLIMIC (Inst); Daiichi Sankyo co.,Ltd. (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); JIMRO (Inst); Kowa (Inst); Medicos Hirata (Inst); Mitsubishi Tanabe Pharma (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K. (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Shionogi (Inst); Sumitomo Dainippon Pharma Co.,Ltd. (Inst); Takeda (Inst); Tsumura & Co. (Inst)